Search
for
Sort by
Research 18
- Therapeutic Strategies to Target the Androgen Receptor
- Clinical Translation of Targeted Protein Degraders
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
- Peptide-Based PROTACs: Transitioning from Static Paradigm to a Dynamic Landscape within Targeted Protein Degradation
- Evolving CRBN ligands enhance the drug-like properties of protein degraders
- Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
- Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
- Advancing Design Strategy of PROTACs for Cancer Therapy
- PROTACs: A novel strategy for cancer drug discovery and development
- Protein degradation: expanding the toolbox to restrain cancer drug resistance
- Emerging Strategies in Smart Nano-PROTAC for Stimuli-Responsive Protein Degradation and Precision Cancer Therapy
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
- Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems
- Protein Immobilization on Bacterial Cellulose for Biomedical Application
- De Novo-Designed Bifunctional Proteins for Targeted Protein Degradation
- De novo designed bifunctional proteins for targeted protein degradation
- <i>De novo</i> designed bifunctional proteins for targeted protein degradation
- Recent Advances in Genome-Editing Technology with CRISPR/Cas9 Variants and Stimuli-Responsive Targeting Approaches within Tumor Cells: A Future Perspective of Cancer Management